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Abstract: Fibromyalgia (FM) is a common, chronic pain disorder with unknown etiology, 
characterized by widespread musculoskeletal pain and tenderness, and accompanied by several 
other symptoms such as sleep disturbance, fatigue, and mood disorders. Pregabalin is the 
ﬁ  rst drug approved for the treatment of FM. Pregabalin has analgesic, anticonvulsant, and 
anxiolytic activity and has earlier demonstrated efﬁ  cacy in the management of neuropathic pain 
associated with diabetic peripheral neuropathy, postherpetic neuralgia, and as adjuvant therapy 
for adult patients with partial onset seizures. Pregabalin, a lipophilic gamma-aminobutyric 
acid (GABA) analog, is α2δ-1 ligand that binds to, and modulates, voltage-gated calcium 
channels. This modulation is characterized by a reduction of the excessive neurotransmitter 
release that is observed in certain neurological and psychotic disorders. Several randomized, 
double-blind, placebo-controlled studies have demonstrated that pregabalin has been effective 
in pain management, improving sleep quality and fatigue, as well as in several domains of 
health related quality of life. Because of mild to moderate adverse effects it can be considered 
a well-tolerated therapy for FM.
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Introduction
Fibromyalgia (FM) is a common, chronic pain disorder with unknown etiology, 
characterized by widespread musculoskeletal pain and tenderness. It has a prevalence 
of about 2% in the US population (Wolfe et al 1995) and 1% to 11% in other countries 
(McBeth and Jones 2007), and it is more common in adult women than in men, with 
prevalence of 3.4% vs 0.5%, respectively (Wolfe et al 1995). The prevalence of FM 
increase with age, ( 7.0% in women) with highest values observed between 60 and 
79 years (Pongratz and Sievers 2000). Clinical studies have demonstrated that the 
anti-seizure drug pregabalin is effective in the treatment of FM and its related symptoms 
(Lyrica®; Owen 2007). Pregabalin (Lyrica®; Pﬁ  zer Inc.) has been approved in 2007 by 
the US Food and Drug Administration (FDA) as the ﬁ  rst drug for the treatment of ﬁ  bro-
myalgia, effective in reducing symptoms of pain, disturbed sleep and fatigue. Pregabalin 
(S-isobutyric gamma-aminobutiric acid, Figure 1), a second generation anticonvulsant, is 
a gamma-aminobutiric acid (GABA) analog with a similar structure and mechanism of 
action to gabapentin. It is a pharmacologically active S-enantiomer of racemic 3-isobutyl 
GABA which has been developed as a follow-up compound to gabapentin, an agent 
with proven antiepileptic, analgesic and anxiolytic activity (Lyrica®).
Pregabalin has been approved earlier by the FDA for the treatment of neuropathic 
pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and 
as adjunctive therapy for refractory partial seizures (Frampton and Foster 2005; 
Gray 2007; Zareba 2007). Pregabalin has also proven efficacy in adjunctive 
therapy of generalized anxiety disorder, social anxiety disorder and acute pain Neuropsychiatric Disease and Treatment 2008:4(6) 1194
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(Lyrica®; MICROMEDEX®). This review focuses on the 
pharmacology, mechanism of action, and clinical studies 
of pregabalin in FM therapy.
Fibromyalgia
According to the criteria published in 1990 by the American 
College of Rheumatology, FM is deﬁ  ned as widespread 
pain of at least 3 months’ duration and pain on palpation of 
at least 11 of 18 speciﬁ  c tender sites on the body (Merck; 
Wolfe et al 1990). Pain, fatigue, and sleep disturbance are 
observed in all patients (Mease 2005). Additional features 
of FM include stiffness, skin tenderness, postexertional 
pain, irritable bowel syndrome, cognitive disturbances, 
overactive bladder syndrome or interstitial cystitis, tension 
or migraine headaches, dizziness, ﬂ  uid retention, pares-
thesias, restless legs, Raynaud’s phenomenon, and mood 
disturbances (Bennet 1999; Mease 2005). FM is strongly 
associated with additional symptoms such as anxiety 
and depressive syndromes, chronic fatigue syndrome, 
myofascial pain syndrome, hypothyroidism, and many of 
the inﬂ  ammatory rheumatic diseases (Aaron et al 2000; 
Mease 2005). Several studies suggest that neurotransmitter 
function deregulation, particularly serotonin, norepinephrine, 
and substance-P, and an abnormality of sensory process-
ing within the central nervous system are involved in the 
pathophysiology of FM (Bennet 1999; Mease 2005). The 
diagnosis is made clinically, with no laboratory or radio-
logical tests available. In clinical practice FM is difﬁ  cult 
to diagnose since many symptoms characteristic for FM 
are also observed in other patients with chronic pain. 
For example, 80% of patients with FM also fulﬁ  ll criteria 
for chronic fatigue syndrom (Aaron and Buchwald 2001). 
Several studies have demonstrated that many patients with 
FM suffer signiﬁ  cant disability and reduced quality of life 
(Mease 2005; Rooks 2007; Wu et al 2007).
In FM patients, altered pain processing as evidenced 
by brain imaging and a 3-fold higher concentration of 
cerebrospinal fluid substance P has been demonstrated 
(Russell et al 1994; Goldenberg 2007). A genetic and 
neuroendocrine predisposition has also been reported. 
In ﬁ  rst degrees relatives of FM patients, an approximate 
8-fold greater risk of developing FM has been observed 
(Arnold et al 2004a). Speciﬁ  c polymorphisms in the serotonin 
transporter gene and the catechol-O-methyltransferase 
(enzyme inactivating catecholoamines) have been associated 
with FM occurrence (Cohen et al 2002; Gursay et al 2003). 
The lower pain threshold in FM patients involves a com-
plex variety of neural pathways and neurotransmitters (ie, 
serotonin, norepinephrine), especially those critical to pain 
inhibition (Staud 2006; Goldenberg 2007; Crofford 2008).
In clinical trials on FM, pain has been the most common 
outcome measure and it has been generally evaluated with 
100 mm numerical rating scales (NRS), visual analog scales 
(VAS), or the brief pain inventory (BPI) (Goldenberg 2007; 
Rooks 2007). Body function is assessed by self-reported, 
validated instruments, most often the ﬁ  bromyalgia impact 
questionnaire (FIQ) which is a 10-item, reliable measure 
of physical function, common ﬁ  bromyalgia symptoms 
and general well-being over the previous 7 days (Bennett 
2005). Short-Form 36 Health Survey (SF-36) is increasingly 
used as a valid and reliable, self-administered measure 
of physical and emotional function, and quality of life in 
FM patients (Ware and Sherbourne 1992; Kosinski et al 
1999).
Treatment of FM is symptom-based in order to 
alleviate pain, restore sleep and improve physical status. 
It has been demonstrated that many patients with FM 
benefit from a multidisciplinary approach in clinical 
practice (Goldenberg et al 2004; Arnold 2006; Rooks 
2007). Current pharmacological treatment guidelines, 
such as those described by the American Pain Society 
(Burckhard et al 2005), recommend tricyclic antidepres-
sants, analgesics, muscle relaxants, benzodiazepines, 
nonsteroidal anti-inflammatory agents, hypnotics, 
corticosteroids, opiates, and soft tissue injections of 
topical anesthetics (Goldenberg et al 2004; Mease 2005; 
Goldenberg 2007; Crofford 2008). Most of these have 
demonstrated effectiveness in reducing pain, but few have 
been shown to be effective in improving the other major 
symptoms of  FM, such as fatigue, sleep disturbances, and 
mood abnormalities. Clinical studies provide evidence 
that tricyclic antidepressants are the most effective in 
FM treatment but their limitations are mostly due to 
relatively narrow therapeutic index and poor tolerability. 
Better tolerated selective serotonin reuptake inhibitors 
(SSRIs; fluoxetine) and dual serotonin-norepinephrine 
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reuptake inhibitors (SNRIs; milnacipran, duloxetine) have 
demonstrated moderate effectiveness (Goldenberg 2007). 
Tramadol is the only analgesic shown to be helpful in FM 
treatment (Biassi 1998; Goldenberg 2007).
Nonpharmacologic treatments showing beneﬁ  cial effects 
in relieving some symptoms of FM include cognitive behav-
ioral therapy, exercise (strength and ﬂ  exibility training), 
improvement of sleep-related disturbances, and complemen-
tary and alternative medicine, ie, osteopathic manipulations, 
acupuncture, low-power laser therapy, and balneotherapy 
(Arnold 2006; Rooks 2007).
According to Staud et al (2006), three important strate-
gies for FM therapy appear useful at this time: 1) reduction 
of peripheral nociceptive input, particularly from muscles 
(through physical therapy, muscle relaxants, muscle injec-
tions, and anti-inﬂ  ammatory analgesics); 2) improvement 
or prevention of central sensitization (through cognitive 
behavioral therapy, sleep improvement, NMDA receptor 
antagonists, and anti-seizure medications); and 3) treatment 
of negative affect, particularly depression (through pharma-
cological and behavioral treatment).
Pregabalin represents a new option in FM treatment due 
to its higher spectrum of action showing efﬁ  cacy in reducing 
pain and improvement of other accompanying symptoms.
Pregabalin
Mechanism of action
Pregabalin has proven analgesic, anticonvulsant, and 
anxiolytic activity. Multiple cellular effects have been 
proposed for its mechanism of action, including modest 
effects on the GABAnergic neurotransmitter system and on 
voltage-gated potassium channels (Freiman et al 2001; Sills 
2006). However, a single common mechanism, inhibition 
of calcium currents via high-voltage-activated channels 
containing the α2δ-1 subunit, leading in turn to reduced 
neurotransmitter release and attenuation of postsynaptic 
excitability is believed to have a predominate effect on its 
mechanism of action (McClelland et al 2004; Sills 2006). 
This effect has been consistently observed at therapeuti-
cally relevant concentrations in pre-clinical studies with 
pregabalin. Studies on mice with mutations leading to 
the substitution of arginine at position 217 with alanine 
on the α2δ-1 subunit demonstrated this unit to be a target 
for pain control, and that pregabalin, by binding to this 
subunit, achieves its analgesic activity (Field et al 2006). 
Additional animal studies have shown pregabalin’s anti-
convulsant (Vartanian et al 2006) and anxiolytic activity 
(Field at al 2001).
It has been demonstrated that although pregabalin is 
a structural derivative of the inhibitory neurotransmitter 
GABA, it does not bind directly to GABAA, GABAB, 
or benzodiazepine receptors, does not augment GABAA 
responses in vitro, does not alter GABA concentration in 
the animal brain, or have acute effects on GABA uptake or 
degradation (Lyrica®). However, prolonged application of 
pregabalin increases the density of GABA transporter pro-
teins and increases the rate of functional GABA transport. 
Pregabalin does not block sodium channels, is not active at 
opiate receptors, and does not alter cyclooxygenase enzyme 
activity. It is inactive at serotonin and dopamine receptors 
and does not inhibit dopamine, serotonine, or noradrenaline 
reuptake (Lyrica®; MICROMEDEX®).
Pharmacokinetics
After oral administration, pregabalin is well absorbed with 
peak plasma concentrations after 1.5 hours and its bioavail-
ability is approximately 90%. The Cmax and AUC values 
are dose proportional. After repeated administration steady 
state is achieved within 24–48 hours. Food consumption 
does not affect absorption of pregabalin but it reduces Cmax 
by 25%–30% and increases Tmax to approximately 3 hours 
(Selak 2001; Lyrica®).
Pregabalin does not bind to plasma protein and its 
apparent volume of distribution after oral administration 
is approximately 0.5 L/kg. Pregabalin is a substrate for 
the system L transporter responsible for transport of large 
amino acids. In animal studies it has been demonstrated that 
pregabalin crosses the blood–brain barrier. It has also been 
shown that pregabalin crosses the placenta and is present in 
milk of lactating animals (Selak 2001).
Metabolism in liver is negligible (Selak 2001; MICRO-
MEDEX®). Renal excretion is the primary route of elimi-
nation as unchanged pregabalin (92%–99%) and a minor 
metabolism to an N-methylated derivative (0.9%) and an 
unidentiﬁ  ed metabolite (0.4%) (Willmore 2000). Elimina-
tion half-life is 6.3 hours and a mean renal clearance is 
67.0–80.9 mL/min in young healthy subjects. Pregabalin 
elimination is nearly proportional to creatinine clearance. 
In patients with renal dysfunction dose reduction is neces-
sary and in patients on chronic hemodialysis, supplemental 
pregabalin may be required due to reduction in pregabalin 
plasma concentration by 50% (Randinitis et al 2003). No 
drug interactions with oral contraceptives, lorazepam, oxyco-
done, ethanol, phenytoin, carbamazepine, valproic acid, and 
lamotrigine were observed (Brodie et al 2005). Pregabalin 
absorption was unaffected by gabapentin coadministration, Neuropsychiatric Disease and Treatment 2008:4(6) 1196
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although a small reduction in the rate of absorption was 
observed (MICROMEDEX®).
Clinical efﬁ  cacy studies
In a multicenter, double-blind, placebo-controlled, 8-week 
randomized efﬁ  cacy and safety clinical trial (Crofford et al 
2005), the effects of pregabalin (administered at the doses of 
150, 300, or 450 mg/day) on pain, sleep, fatigue, and health-
related quality of life were studied in 529 patients with FM. 
The comparison of end point mean pain scores from daily 
diary ratings of pain intensity between each of the prega-
balin treatment groups and the placebo group revealed that 
pregabalin at 450 mg/day signiﬁ  cantly reduced the average 
severity of pain in the primary efﬁ  cacy analysis as compared 
with placebo (–0.93 on a 0–10 scale; p   0.001). The 
improvement in pain  50% at the end point was observed 
in patients from the same group (29%, vs 13% in the placebo 
group; p = 0.003). Pregabalin administration at doses 300 and 
450 mg/day was associated with signiﬁ  cant improvements 
in sleep quality, fatigue, and global measures of change. 
Pregabalin at the dose of 450 mg/day improved several 
domains of health-related quality of life. End point scores 
were signiﬁ  cantly higher than those obtained in the placebo 
group in social functioning, bodily pain, vitality, and general 
perception in the SF-36 Health Survey. Most adverse events 
were mild or moderate with the most frequently observed 
being dizziness and somnolence. Rates of discontinuation 
due to dizziness and somnolence were similar across all 
4 treatment groups. Non-central nervous system adverse 
events including weight gain (no withdrawal) and peripheral 
edema (1 patient) with no changes in cardiovascular or renal 
function were observed.
FM is frequently associated with anxiety and depressive 
symptoms which are reported by approximately 1/3 of 
patients (Wolfe et al 1995; White et al 2002; Antai-Otong 
2005). Arnold et al (2007) assessed the prevalence and 
severity of anxiety and depressive symptoms in FM patients, 
using the patient-reported Hospital Anxiety and Depression 
Scale in a previously described cohort (Crofford et al 2005). 
In order to determine the impact of these symptoms on 
response to pain reduction after the treatment of patients with 
pregabalin (N = 529), the association between improvements 
in anxiety and depression and pain relief were evaluated. It 
has been shown that signiﬁ  cantly more patients reported 
anxiety symptoms (71%) than depressive symptoms (56%, 
p   0.0001). Much of the pain reduction appeared to be 
independent of improvements in anxiety or mood symptoms. 
Pregabalin reduced pain in patients with or without anxiety 
or depressive symptoms, suggesting that pregabalin would 
be efﬁ  cacious in patients regardless of these symptoms.
Pregabalin has also been studied in combination 
therapy of FM. Calandre et al (2007) conducted an open-
label, 12-week study in 19 female FM patients currently 
being treated with quetiapine (76 mg/day). Pregabalin 
was introduced at a starting dose of  75 mg/day which was 
subsequently adjusted according to the drug’s efﬁ  cacy and 
tolerability (range 75–300 mg/day). Outcome measures 
included the FIQ, the Pittsburgh Sleep Quality Index, the 
Beck Depression Inventory, the State and Trait Anxiety 
Inventory, and the SF-12 Health Survey. Pregabalin sig-
niﬁ  cantly improved the pain and tiredness after awakening 
subscales of the FIQ as well as the physical component of 
the SF-12. Out of 6 patients who withdrew from the study, 
3 did it because of side effects. Studies demonstrated that 
the use of combined therapy of pregabalin and quetiapine 
can be a useful augmentation strategy in the treatment of 
ﬁ  bromyalgia patients.
In the recently published multicenter, double-blind, 
placebo-controlled randomized trial on pregabalin’s 
efﬁ  cacy and safety, 748 patients with FM received placebo 
or pregabalin at doses of 300, 450, or 600 mg/day, twice 
daily for 13 weeks (Mease et al 2008). The evaluation of 
symptomatic relief of pain associated with FM was based 
on comparison of endpoint mean pain scores between each 
pregabalin group and placebo. Another outcome variable, 
management of FM, included endpoint mean pain scores, 
Patient Global Impression of Change (PGIC), and the FIQ 
-Total Score. Secondary outcomes included assessments of 
sleep, fatigue, and mood disturbance. In all pregabalin treated 
patients statistically signiﬁ  cant improvement in endpoint 
mean pain score and in PGIC response was observed as 
compared with placebo. Statistically signiﬁ  cant improve-
ment in assessments of sleep, the MOS-Sleep Disturbance, 
MOS-Sleep Quantity subscale, Sleep Problem Index, and 
in patients’ impressions of their global improvement was 
observed in all pregabalin treatment groups. The most fre-
quently reported adverse events were dizziness, somnolence, 
headache, infection, and weight gain. All these effects were of 
mild or moderate intensity. Dizziness and somnolence were 
the adverse effects that most frequently led to withdrawal 
among pregabalin treated patients (9% and 6%, respectively). 
A dosage related increase in patient’s withdrawal due to 
any adverse effects (11%, 19%, 22%, and 33% for placebo, 
300, 450, and 600 mg/day pregabalin groups, respectively) 
was observed. Sixty-six patients (11.8%) experienced a 
clinically signiﬁ  cant increase in body weight of 7% or Neuropsychiatric Disease and Treatment 2008:4(6) 1197
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more from baseline to end of treatment; however, none of 
the patients with weight gain  7% discontinued treatment 
prematurely.
A long-term, multicenter, double-blind, placebo-controlled, 
randomized discontinuation trial (FREEDOM) demonstrated 
the durability of pregabalin effects for relieving FM pain in 
patients who responded to the treatment (Crofford et al 2008). 
The trial, performed in adults with FM and  40-mm 
score using 100-mm VAS, included a 6-week open-label 
pregabalin treatment phase (N = 1051) followed by 26-week, 
double-blind treatment phase with placebo or pregabalin. 
During the open label weeks 1–3, patients received escalating 
dosages of pregabalin to determine their optimal dosages, and 
during open label weeks 4–6, patients received their optimal 
ﬁ  xed dosages (300, 450, 600 mg/day). To be randomized, 
patients must have had  50% decrease in pain VAS and a 
self-rating of “much” or “very much” improved on PGIC at 
the end of the open label period. In the double-blind treatment 
phase patients received placebo or the patient’s optimal ﬁ  xed 
dosage of pregabalin. Time to loss of therapeutic response 
(LTR), deﬁ  ned as  30% reduction in pain (from open label 
baseline) or worsening of FM was a primary outcome. Out of 
all patients who entered the open label phase, 287 were 
randomized to placebo and 279 to pregabalin treatment. The 
observed time to LTR was longer for the pregabalin group 
as compared to placebo (p   0.0001). Kaplan–Meier esti-
mates of time-to-event showed half the placebo group had 
LTR by Day 19 (Figure 2); half the pregabalin group still 
had not lost response by trial end. At the end of the double 
blind period, 174 (61%) placebo patients met LTR criteria 
versus 90 (32%) pregabalin patients. During the open label 
phase 178 patients (17%) discontinued participation in the 
study due to treatment-related adverse events. During the 
double-blind phase 16% of pregabalin compared with only 
7% of patients receiving placebo discontinued treatment due 
to adverse effects.
Another recently published study on the efficacy 
and safety of pregabalin monotherapy demonstrated 
that pregabalin is an important treatment option for FM 
patients (Arnold et al 2008). In a randomized, double-
blinded, placebo-controlled trial, 750 patients meeting 
American College of Rheumatology criteria for FM were 
randomly assigned to pregabalin (300 mg/day, 450 mg/day, 
600 mg/day) or placebo, administered twice daily for 
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Figure 2 Kaplan-Meier plot of time to loss of therapeutic effect. Comparison (log-rank test) with placebo, p   0.0001. Reproduced with permission from Crofford LJ, Mease 
PJ, Simpson SL, et al 2008. Fibromyalgia relapse evaluation and efﬁ  cacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with 
pregabalin. Pain, 136:419–31. Copyright © 2008 Elsevier.Neuropsychiatric Disease and Treatment 2008:4(6) 1198
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14 weeks. The primary outcome variable was comparison 
of end point mean pain scores, derived from daily diary 
ratings of pain intensity (0–10 scale), between each of the 
pregabalin groups and the placebo group. Mean changes in 
pain scores at the end point in pregabalin treated patients 
were significantly greater (p   0.001: 300 mg/day, –
0.71; 450 mg/day –0.98; 600 mg/day, –1.00) than in the 
placebo group. Pregabalin-treated patients reported improve-
ment on PGIC (p   0.01 for all 3 pregabalin doses) and sig-
niﬁ  cant improvements in total FIQ score for the 450 mg/day 
(p = 0.004) and the 600 mg/day (p = 0.003) doses. All 3 doses 
of pregabalin were associated with signiﬁ  cant improvement 
in sleep. The most commonly reported pregabalin-related 
adverse events were dizziness and somnolence, which 
appeared to have been dose-related.
Gabapentin, a precursor of pregabalin, has been 
approved by the FDA for the treatment of postherpetic 
neuralgia and for adjunctive treatment of epilepsy, and it 
has also been evaluated in FM patients in a randomized, 
double-blind, placebo-controlled study (Arnold et al 2007). 
Gabapentin (1,200–2,400 mg/day) was administered to 
patients (N = 75) for 12 weeks. Gabapentin-treated patients 
displayed a signiﬁ  cantly greater improvement in the BPI 
average pain severity score (p = 0.015; estimated differ-
ence between groups at week 12 = –0.92). A signiﬁ  cantly 
greater proportion of gabapentin treated patients compared 
with placebo-treated patients achieved response at the end 
point (51% vs 31%; p = 0.014). Gabapentin compared with 
placebo also signiﬁ  cantly improved the BPI average pain 
interference score, the Fibromyalgia Impact Questionnaire 
total score, the Clinical Global Impression of Severity, the 
Patient Global Impression of Improvement, the Medical 
Outcomes Study (MOS) Sleep Problems Index, and the MOS 
Short Form 36 vitality score, but not the mean tender point 
pain threshold or the Montgomery Asberg Depression Rating 
Scale. Gabapentin was generally well tolerated. However, 
as compared with placebo, a signiﬁ  cantly higher incidence 
of sedation, lightheadedness, and dizziness was observed in 
gabapentin patients.
It should be pointed out that the primary outcome mea-
sure used in most clinical trials on FM is mean reduction in 
pain intensity and according to several authors, this approach 
does not adequately address the critical question of whether 
or not a statistically signiﬁ  cant reduction in pain intensity 
versus placebo with a given treatment is clinically signiﬁ  -
cant or meaningful (Mease 2005). Staud and Price (2008) 
pointed out that although an enrichment design applied 
in some studies on pregabalin (Mease et al 2008) can be 
efﬁ  cacious clinically, the prior exposure to an experimental 
treatment in open-label qualiﬁ  cation phase may invalidate 
drug-placebo comparisons made during a later randomized, 
double-blind phase.
Safety and tolerability
Adverse effects in clinical trials conducted under widely 
varying conditions varied for different disorders and have 
been described separately elsewhere (Lyrica®). In all pre-
marketing trials of all populations combined, 14% of prega-
balin-treated patients and 7% of placebo-obtaining patients 
discontinued prematurely due to adverse effects. In prega-
balin patients, the observed withdrawal was mostly due to 
dizziness (4%) and somnolence (3%), whereas in the placebo 
group discontinuation due to the same adverse effects was 
1% and  1%, respectively. In clinical trials of FM patients, 
19% of patients treated with pregabalin (150–600 mg/day) 
discontinued treatment due to adverse reactions, mostly diz-
ziness (6%) and somnolence (3%), whereas 10% of patients 
obtaining placebo withdrew due to the same adverse effects 
(Lyrica®).
The most frequently reported adverse effects of pre-
gabalin in clinical trials of patients with FM were dose 
related and observed within 150–600 mg/day vs placebo: 
dizziness (23%–38% vs 9% ), somnolence (13%–22% 
vs 4%), headache (11%–10% vs 12%), weight increase 
(8%–14% vs 2%), fatigue (5%–8% vs 4%), and balance 
disorder (2%–9% vs 0%) (Lyrica®). These adverse effects 
were usually mild or moderate in severity. However, Mease 
et al (2008) reported recently a higher incidence of dizzi-
ness (42%) and somnolence (26%) which can indicate that 
patients with FM may be more sensitive to central nervous 
system related adverse effects. Non-central nervous system 
events observed more frequently in the pregabalin-treated 
patients included also peripheral edema. No changes in 
cardiovascular or renal function were observed in patients 
who developed peripheral edema. There were no clinically 
relevant differences in clinical laboratory evaluations, vital 
signs, physical examination ﬁ  ndings, or electrocardiogram 
ﬁ  ndings (Lyrica®; MICROMEDEX®).
Other new developments
in ﬁ  bromyalgia treatment
Several different pharmacological approaches have been 
undertaken in FM management. Besides described above 
clinical trials on α2δ-1 ligands, selective SNRIs such as 
duloxetine and milnacipram demonstrate the biggest promise. 
Similarly to pregabalin, they reduce not only pain, the primary Neuropsychiatric Disease and Treatment 2008:4(6) 1199
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symptom of FM, but also improve other symptom domains, 
and some aspects of function and global assessments.
Duloxetine has been approved by the FDA for the treatment 
of major depressive disorder, generalized anxiety disorder, 
diabetic peripheral neuropathic pain and FM. A randomized, 
double-blind, placebo-controlled, multicenter study evaluated 
the efﬁ  cacy and safety of duloxetine in subjects with primary 
FM (Arnold 2004b). Patients (N = 207, 38% with current 
major depressive disorder) received duloxetine 60 mg twice 
daily or placebo for 12 weeks. Duloxetine was an effective 
and safe treatment for many of the symptoms associated with 
FM in subjects with or without major depressive disorder, 
particularly for women, who had signiﬁ  cant improvement 
across most outcome measures. Difﬁ  culty sleeping, oral 
dryness and constipation were the most frequently reported 
adverse effects in the duloxetine group.
Duloxetine was also studied in a 12-week, randomized, 
double-blind, placebo-controlled trial in 354 female patients 
with primary FM, with or without current major depressive dis-
order (Arnold 2005). Patients received duloxetine 60 mg once 
daily (N = 118) or twice daily (N = 116), or placebo (N = 120). 
Both duloxetine treated groups improved signiﬁ  cantly on aver-
age pain severity score. The decrease of pain score was 55%, 
54%, and 33% (duloxetine once daily, duloxetine twice daily 
and placebo, respectively). The treatment effect of duloxetine 
on pain reduction was independent of the effect on mood and 
the presence of major depressive disorder. Patients treated with 
duloxetine had signiﬁ  cantly greater improvement in BPI, pain 
severity and interference scores, FIQ, Clinical Global Impres-
sion of Severity, Patient Global Impression of Improvement, 
and several quality of life measures. The adverse effects were 
generally mild to moderate in severity with the most frequently 
observed being nausea.
Milnacipran, another selective SNRI has been approved 
in 1997 in Europe, Asia, and other countries for the treatment 
of depression but it is unavailable in the US. Milnacipram 
has been studied in 125 patients (98% women) with FM 
(Gendreau et al 2005). In a double-blind dose escalation 
Phase II study, patients were randomly assigned in a 3:3:2 
ratio to receive milnacipran twice daily, milnacipran once 
daily, or placebo for 3 months. Dose escalation to the target 
milnacipran dose of 200 mg was achieved in 92% of twice 
daily and 81% of once daily participants. The twice daily 
milnacipran group showed statistically signiﬁ  cant improve-
ments in the weekly diary pain scores and more patients 
(37%) reported a reduction in the weekly average pain scores 
by  50%. In both once daily and twice daily milnacipram 
groups, improvements in global well being, fatigue, and other 
domains were observed. Response rates for patients receiving 
milnacipran were equal in patients with and without comorbid 
depression, but placebo response rates were considerably 
higher in depressed patients, leading to signiﬁ  cantly greater 
overall efﬁ  cacy in the nondepressed group. Milnacipran was 
generally well tolerated. Patient withdrawal due to adverse 
events was 14.4%, with most commonly reported symptoms 
being headache and gastrointestinal problems (nausea, 
abdominal pain, constipation). Other adverse effects included 
orthostatic dizziness, hypertension, depression, lethargy, 
sweating, and hot ﬂ  ashes.
Clinical trials of SSRIs, ﬂ  uoxetine (Wolfe et al 1994), and 
citalopram (Nørregaard et al 1995) have demonstrated mixed 
responses suggesting less consistent results than described 
above SNRIs (Arnold 2006).
Sedative hypnotics, such as sodium oxybate (sodium 
salt of gamma-hydroxybutyrate, precursor of GABA), used 
for the treatment of cataplexy and narcolepsy, have been 
also evaluated in FM treatment due to often observed sleep 
disturbances in FM patients (Russell 1999; Scharf et al 2003). 
However, a high risk of abuse, lethality at supratherapeutic 
doses or risk of  hypnotic use, make usefulness of these drugs 
questionable (Grifﬁ  ths and Johnson 2005).
Similar controversy may be associated with use of 
opiates. Tramadol, a novel analgesic with weak agonist 
activity at the mu opiate receptor combined with dual 
serotonin and norepinephrine reuptake inhibition, has been 
studied in several FM clinical trials (Biasi et al 1998; Bennett 
et al 2003). However, tramadol use has been associated 
with increased number of reports on abuse, dependency and 
presence of classic opioid withdrawal symptoms (Senay 
et al 2003).
Other new pharmacological approaches to FM treat-
ment such as the use of 5-HT 3 antagonists (tropisteron) 
(Färber et al 2000; Späth et al 2004), NMDA antagonists 
(dextromethorphan) (Henriksson and Sorensen 2002; Staud 
et al 2005), or dopamine 3 receptor agonists (pramipexole) 
(Holman and Myers 2005) show some promising results. 
However, more studies are needed before their use can be 
considered for FM treatment.
Conclusions
FM is a chronic pain disorder which causes pain, fatigue, 
reduced quality of life, and disability. Although recent 
studies support the recommendation of a multidisciplinary 
approach in clinical practice, pharmacologic treatment 
remains the primary approach to management of patients 
with FM. Treatment goals include the improvement of Neuropsychiatric Disease and Treatment 2008:4(6) 1200
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symptoms, primarily pain and sleep, and the promotion of 
improvement of physical function, emotional well-being 
and other symptoms associated with FM. The complexity 
of FM makes it challenging for pharmaceutical companies 
to mount effective clinical trials to assess emerging thera-
pies. Randomized controlled trials are generally difﬁ  cult 
due to some factors such as a lack of understanding of 
the pathophysiology or heterogeneity of the FM patient 
population. However, results of several clinical studies 
have been already published and more are taking place to 
identify different potential therapeutic approaches. Ongoing 
clinical trials on newer agents seem promising, however 
the efﬁ  cacy of all these agents has not been compared with 
pregabalin yet. Pregabalin offers several practical proper-
ties, such as lack of protein-binding and hepatic metabolism, 
and linear pharmacokinetics across its therapeutic range. 
Together with its demonstrated safety and tolerability, 
pregabalin represents an important new option for the 
treatment of FM.
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